Skip to main content

Table 1 Basic demographic, clinical characteristics and CA 19 − 9 levels of diabetic inpatients

From: Effect of glycotoxicity and lipotoxicity on carbohydrate antigen 19 − 9 in the patients with diabetes

 

The HbA1c < 9% group

(n = 199)

The HbA1c ≥ 9% group

(n = 186)

p value

CA 19−9 levels (U/ml)

14.8 ± 9.6

22.0 ± 17.4

< 0.001*

Proportion of patients with abnormal CA 19−9

6/199 (3.0%)

26/186 (14.0%)

< 0.001*

Age (years)

59.9 ± 11.6

55.4 ± 13.3

< 0.001*

Female sex

62 (31.2%)

49 (26.3%)

0.298

BMI (kg/m2)

25.2 ± 3.2

24.8 ± 3.7

0.240

HbA1c (%)

7.26 ± 0.98

11.37 ± 1.91

< 0.001*

Systolic blood pressure (mmHg)

133.4 ± 19.7

128.9 ± 20.2

0.027

Diastolic blood pressure (mmHg)

79.9 ± 11.5

81.5 ± 12.1

0.173

Uric acid (µmol/l)

330.1 ± 93.8

305.7 ± 94.2

0.012

Total cholesterol (mmol/l)

4.59 ± 1.24

4.77 ± 1.27

0.157

Triglycerides (mmol/l)

1.84 ± 1.64

2.02 ± 1.82

0.314

Creatinine (µmol/l)

72.0 ± 27.6

64.6 ± 23.2

0.005*

ALT (U/L)

25.2 ± 15.0

26.6 ± 17.6

0.406

  1. CA 19 − 9, carbohydrate antigen 19 − 9; BMI, body mass index; HbA1c, glycosylated hemoglobin; ALT, alanine aminotransferase; * p value was less than 0.01